1. Home
  2. STTK vs ULBI Comparison

STTK vs ULBI Comparison

Compare STTK & ULBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STTK
  • ULBI
  • Stock Information
  • Founded
  • STTK 2016
  • ULBI 1990
  • Country
  • STTK United States
  • ULBI United States
  • Employees
  • STTK N/A
  • ULBI N/A
  • Industry
  • STTK Biotechnology: Pharmaceutical Preparations
  • ULBI Industrial Machinery/Components
  • Sector
  • STTK Health Care
  • ULBI Miscellaneous
  • Exchange
  • STTK Nasdaq
  • ULBI Nasdaq
  • Market Cap
  • STTK 173.6M
  • ULBI 158.1M
  • IPO Year
  • STTK 2020
  • ULBI 1992
  • Fundamental
  • Price
  • STTK $3.73
  • ULBI $9.49
  • Analyst Decision
  • STTK Strong Buy
  • ULBI Strong Buy
  • Analyst Count
  • STTK 3
  • ULBI 1
  • Target Price
  • STTK $10.67
  • ULBI $14.00
  • AVG Volume (30 Days)
  • STTK 122.9K
  • ULBI 43.2K
  • Earning Date
  • STTK 11-07-2024
  • ULBI 10-24-2024
  • Dividend Yield
  • STTK N/A
  • ULBI N/A
  • EPS Growth
  • STTK N/A
  • ULBI 283.01
  • EPS
  • STTK N/A
  • ULBI 0.60
  • Revenue
  • STTK $4,123,999.00
  • ULBI $168,946,000.00
  • Revenue This Year
  • STTK $164.45
  • ULBI $10.59
  • Revenue Next Year
  • STTK N/A
  • ULBI $8.72
  • P/E Ratio
  • STTK N/A
  • ULBI $15.71
  • Revenue Growth
  • STTK 380.09
  • ULBI 17.37
  • 52 Week Low
  • STTK $1.33
  • ULBI $6.36
  • 52 Week High
  • STTK $11.76
  • ULBI $13.39
  • Technical
  • Relative Strength Index (RSI)
  • STTK 50.03
  • ULBI 42.40
  • Support Level
  • STTK $3.63
  • ULBI $9.24
  • Resistance Level
  • STTK $3.94
  • ULBI $9.69
  • Average True Range (ATR)
  • STTK 0.23
  • ULBI 0.38
  • MACD
  • STTK 0.04
  • ULBI -0.00
  • Stochastic Oscillator
  • STTK 49.12
  • ULBI 24.71

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.

About ULBI Ultralife Corporation

Ultralife Corp provides products and services ranging from power solutions to communications and electronics systems to customers across the globe in the government and defense, medical, safety and security, energy, and industrial sectors. The company designs, manufactures, installs, and maintains power and communications systems including rechargeable and non-rechargeable batteries, charging systems, communications and electronics systems and accessories, and custom-engineered systems. The company's segments include Battery and Energy Products, and Communications Systems. It generates maximum revenue from the Battery and Energy Products segment, and from the U.S. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical, and various other non-rechargeable batteries.

Share on Social Networks: